NATIONAL RESEARCH CORP

Company Overview

NATIONAL RESEARCH CORP (NRC) is a Healthcare company in the Health Information Services industry that provides a subscription-based, AI-enabled platform to measure and improve patient, consumer, employee and market experiences for health systems. Its offerings include CAHPS-compliant patient surveys, syndicated market-insights data, reputation and service-recovery tools, employee-experience analytics and governance services, with Huey (an embedded AI engine) across the stack. NRC’s business model emphasizes recurring, fixed-price subscriptions, cross-selling to an installed base (over 250 of the top 400 health systems), and growth via product expansion and strategic acquisitions; the firm has notable revenue visibility from recurring contracts but recently experienced TRCV and revenue declines. Key operational exposures include CMS/CAHPS regulatory dependence, cybersecurity and talent retention, and sensitivity to client renewals and industry consolidation.

Executive Compensation Practices

Executive pay at NRC appears tied to subscription metrics and margins—key drivers include TRCV (total recurring contract value), retention/renewal rates, recurring revenue growth, operating income, and successful M&A integration. Recent filings show elevated cash bonuses and materially higher share‑based compensation following the June 1, 2025 CEO appointment (including a roughly $4.9M one‑time signing charge and ongoing non‑cash equity charges of about $770k quarterly through March 2028), plus higher compensation for strategic hires; these moves indicate a shift to reward growth, retention and strategic execution. The company also uses stock repurchases and dividends as capital-allocation levers ( ~$30.8M repurchased in 2024 and ongoing repurchase activity in 2025), which can interact with equity-based pay and long‑term incentive pacing. Given NRC’s SaaS-like recurring model and comparables in Health Information Services, compensation packages typically blend base salary, cash incentives tied to renewal/retention and financial targets, and equity grants to align executives with multi-year TRCV and margin improvement goals.

Insider Trading Considerations

Insiders at NRC will likely time trades around cyclical renewal disclosures, TRCV updates and earnings releases because those metrics materially affect valuation and incentive outcomes; vesting events from recent executive grants and the CEO signing package are potential catalysts for insider sales. The company’s material borrowings, floating‑rate exposure and working‑capital swings (working‑capital deficits and evolving revolver/delayed‑draw usage) create additional materially non‑public information that could trigger blackout periods or heighten regulatory risk for insider transactions. Given dependency on CMS/CAHPS and client-renewal signals, insiders should observe stricter trading windows, consider Rule 10b5‑1 plans to manage perceived conflicts, and be mindful that activist or acquisitive activity (Nobl acquisition history) and covenant compliance can produce sudden, market‑moving news. Finally, ongoing repurchases/dividends and relatively concentrated top-client exposure mean insiders may both buy opportunistically during buybacks or face pressure to diversify holdings following large equity awards.